Completed PHASE4 INTERVENTIONAL 2-arm NCT05614362

Channa Striatus Extract on Albumin and Hs-CRP ESRD

The Effect of Channa Striatus Extract on Serum Albumin and High Sensitive C-Reactive Protein in End-Stage Renal Disease Patients

Sponsor: Universitas Sebelas Maret

Conditions End-Stage Renal Disease Inflammation

Interventions Channa Striatus extract Maltodextrin

Updated 3 times since 2022 Last updated: Nov 6, 2022 Started: Jan 1, 2021 Primary completion: Mar 1, 2021 Completion: Mar 1, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates End-Stage Renal Disease and Inflammation and is currently completed. Universitas Sebelas Maret leads this study, which shows 3 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Dec 2022 — Jul 2024 [monthly]

Completed PHASE4

First recorded

Jan 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Universitas Sebelas Maret

Data source: Universitas Sebelas Maret

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Surakarta, Indonesia